Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 12 January 2026Published: 23 June 2015
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) (TA1068)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 May 2025
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal) (TA980)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 5 June 2024
Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 7 February 2024
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2022
Melanoma: assessment and management (NG14)Product type:GuidanceProgramme:NICE guidelineLast updated: 27 July 2022Published: 29 July 2015
Cemiplimab for treating advanced cutaneous squamous cell carcinoma (TA802)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 June 2022
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma (TA766)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Avelumab for treating metastatic Merkel cell carcinoma (TA517)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 21 April 2021Published: 11 April 2018
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 April 2021
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA684)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 March 2021
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 March 2019
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 February 2019
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma (TA544)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 October 2018
Vismodegib for treating basal cell carcinoma (TA489)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 November 2017
Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 25 November 2015
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 12 September 2017Published: 7 October 2015
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 August 2017
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma (TA414)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2016
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2016
Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 February 2016
Skin cancer prevention (PH32)Product type:GuidanceProgramme:Public health guidelineLast updated: 9 February 2016Published: 26 January 2011
Sunlight exposure: risks and benefits (NG34)Product type:GuidanceProgramme:NICE guidelinePublished: 9 February 2016
VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)Product type:GuidanceProgramme:HealthTech guidancePublished: 11 November 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma (TA269)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 1 January 2015Published: 12 December 2012
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 October 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 July 2014
Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 December 2012
Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)Product type:GuidanceProgramme:HealthTech guidancePublished: 25 July 2011
Improving outcomes for people with skin tumours including melanoma (CSG8)Product type:GuidanceProgramme:Cancer service guidelineLast updated: 25 May 2010Published: 22 February 2006
Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (TA145)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2008
Digital technologies for the detection of melanoma (MIB311)Product type:AdviceProgramme:Medtech innovation briefingPublished: 1 November 2022
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)Product type:AdviceProgramme:Medtech innovation briefingPublished: 5 May 2022
Skin cancer (QS130)Product type:Quality standardLast updated: 24 January 2024Published: 21 September 2016
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 21 April 2021
Suspected Cancer: recognition and referral (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 25 March 2026
Lifileucel for previously treated unresectable or metastatic melanoma ID3863Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 10 July 2026
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID5113]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
EchoLaser percutaneous laser ablation treatment for patients with neck lesionsStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tiragolumab with atezolizumab for treating advanced oesophageal squamous cell cancer after chemoradiotherapy [ID6267]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab–relatlimab for adjuvant treatment of resected stage 3 or 4 melanoma in people 12 years and over [ID6475]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer [ID6490]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Cryoablation for Desmoid-type FibromatosisStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma after surgery and radiotherapy [ID6659]Status:In development | In consultationProgramme:Technology appraisal guidanceConsultation end date: 19 February 2026Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Imsamotide with etimumotide and pembrolizumab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID12279]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [TSID12303]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC